Foodconsumer.org

 
USCards.com Bookmark Us
All Food, Diet and Health News 
 
 Misc. News
 Must-Read News
 Letter to Editor
 Featured Products
 Recalls & Alerts
 Consumer Affair
 Non-food Things
 Health Tips
 Interesting Sites
 
 Diet & Health
 Heart & Blood
 Cancer
 Body Weight
 Children & Women
 General Health
 Nutrition
 
 Food & Health
 Food Chemicals
 Biological Agents
 Cooking & Packing
 Technologies
 Agri. & Environ.
 Laws & Politics
 
 General Health
 Drug News
 Diseases
 Mental Health
 Infectious Disease
 Environment
 Lifestyle
 Government
 Other News
 
 Food Consumer
 FC News & Others
Search





Search Foodconsumer & Others


Add to Google
Add to My Yahoo
Newsfeed

foodconsumer.org news feed
Su bmit news[release]



More than 100 credit cards available at uscards.com from uscards.com, you can pick more than 100 credit cards


General Health : Drug News Last Updated: Apr 20, 2011 - 9:38:09 AM


Diabetes drug Avandia linked to higher risk of death
By Jimmy Downs
Nov 24, 2008 - 3:08:40 PM

E.mail t.his a.rticle
 P.rinter f.riendly p.age
Get n.ewsletter
 
   

Monday Nov 24, 2008 (foodconsumer.org) -- A new study suggests that use of drug rosiglitazone, sold under the brand name Avandia and made by GlaxoSmithKline may significantly increase the risk of heart failure and death than its competitor pioglitazone, sold as Actos and made by Takeda Pharmaceutical Co.

 

The study led by researchers at Harvard Medical School found death rates for patients treated with Avandia were 15 percent more likely and congestive heart failure rates were 13 percent higher than those who took Actos.

 

This is only a suggestion that taken Avandia may increase risk of death and heart failure because the study is an observation but not a trial, meaning that the association between the drug use and an increase in the heart failure and death risk may not be a causal relation.  

 

Glaxo already dismissed the findings saying the results were inconsistent with previous studies.   One trial it referred to is a six-year trial of 4,447 patients, which company officials were cited as noting has found no significant increases in deaths from any cause including cardiovascular disease in patients taking rosiglitazone.

 

For the current study, Dr. Wolfgang C. Winkelmayer, assistant professor of medicine at the Harvard Medical School and first author of the study and colleagues meta-analyzed 42 studies involving 28,361 patients who had been tracked for up to five years.

 

They found patients taking Avandia were at higher risk of heart failure and death than those who took Actos.   But the rates of heart attacks and stroke among those taking Avandia were not greater than that for those using pioglitazone.

 

"In much older adults, it is possible if they do have a stroke or myocardial infarction, they might actually die immediately and never make it to the hospital for a diagnosis, so the excess cardiac events might show up as deaths," Dr. Winkelmayer was quoted by New York Times as saying.

 

The American Diabetes Association and the European Association for the Study of Diabetes have already stopped recommending rosiglitazone for type 2 diabetes.   And the consumer advocate Public Citizen has been pushing the Food and Drug Administration to ban the drug because the not-for-profit organization said last month to the agency that Avandia causes live failure, vision impairment and other serious side effect in addition to high profile cardiovascular risk.

 

Steven Nissen, a prominent heart specialist and chief of cardiovascular medicine at the Cleveland Clinic, one of the best heart clinics in the world, early analyzed data from 42 clinical trials of Avandia and he found that Avandia patients were 43 percent more likely to have a heart attack or be hospitalized for blocked coronary arteries than others in the studies.

 

His findings were reported in the New England Journal, a prestigious medical journal in the world.   But Glaxo based in the United Kingdom claimed that Dr. Nissen's study was flawed and has maintained that Avandia is safe for the heart like other diabetes drugs.

 

The FDA held a hearing last year.   Dr. David Graham of the FDA's Office of Surveillance and Epidemiology told panelists who have the power to determine the fate of the drug that the Glaxo's diabetes drug should come off the market, according to USA Today.  

 

Dr. Graham also said Actos does not increase heart risk like Avandia and suggested that there is no reason for the Glaxo's drug to stay on the market.   But the FDA panel did not heed Dr. Graham's suggestion and voted 22 to 1 to keep the drug on the market.





© 2004-2008 by foodconsumer.org unless otherwise specified

Top of Page




Google
 
Web foodconsumer.org

Search Consumer-friendly Health Sites












We have moved to Food Consumer . Org



disclaimer | advertising | jobs | privacy | about us | newsletter | Submit news/articles
link partners: | Buy Viagra | MarketAmerica.com |
Buy a home | Auto Insurance | Mortgage refinancing | DaytonaCPA.com | Take Your Blog to a Higher Level
© Copyright 2004 - 2008 foodconsumer.org All rights reserved

Disclaimer: What's published on this website should be considered opinions of respective writers only and foodconsumer.org which has no political agenda nor commercial ambition may or may not endorse any opinion of any writer. No accuracy is guaranteed although writers are doing their best to provide accurate information only. The information on this website should not be construed as medical advice and should not be used to replace professional services provided by qualified or licensed health care workers. The site serves only as a platform for writers and readers to share knowledge, experience, and information from the scientific community, organizations, government agencies and individuals. Foodconsumer.org encourages readers who have had medical conditions to consult with licensed health care providers - conventional and or alternative medical practitioners.